PTC Therapeutics Expands Team with Stock Options and RSUs for New Employees

PTC Therapeutics Expands Workforce with New Stock Options and RSUs for Employees

PTC Therapeutics, Inc. announces the approval of stock options and restricted stock units (RSUs) for 15 new employees, marking a significant step in the company’s commitment to fostering a talented workforce. On November 24, 2025, the company’s Compensation Committee grants non-statutory stock options for 2,000 shares of common stock and 8,200 RSUs as an inducement for these hires. This initiative aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing PTC's dedication to attracting skilled professionals in the biopharmaceutical sector.

The stock options come with an exercise price of $79.83 per share, corresponding to the closing price of PTC's common stock on the grant date. These options are structured to vest over a four-year period, with 25% vesting on the first anniversary of each employee's start date and an additional 6.25% vesting every three months thereafter, contingent upon the employees' continued service. This vesting schedule is designed to promote long-term commitment and retention among the new hires, which is essential for the company as it strives to enhance its innovative capabilities in developing therapies for rare disorders.

Alongside the stock options, the RSUs will also vest over four years, with 25% vesting each year on the anniversary of the hire date. The introduction of these financial incentives underscores PTC Therapeutics' strategic approach to building a robust team that can contribute to its mission of delivering transformative therapies for individuals grappling with unmet medical needs. The company’s commitment to leveraging scientific expertise and commercial infrastructure to provide value to patients and stakeholders is reinforced through these new hiring initiatives.

In addition to expanding its workforce, PTC Therapeutics maintains a focus on its diverse pipeline of innovative medicines aimed at addressing rare disorders. The company continues to position itself as a leader in the biopharmaceutical industry, committed to advancing healthcare solutions that improve patients' lives. Interested parties can learn more about PTC's initiatives and developments by visiting their website or engaging with them on social media platforms.